The effect of low dose tolvaptan after cardiovascular surgery

The effect of low dose tolvaptan after cardiovascular surgery - The effect of low dose tolvaptan after cardiovascular surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033992

Enrollment

240

Registered

2018-09-03

Start date

2018-09-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

after cardiovascular surgery associated with cardiopulmonary bypass

Interventions

Azosemide 30 mg / day was administered from the 2nd postoperative day. Administer furosemide 10 to 40 mg as appropriate. Within 4 days to return to preoperative weight. Azosemide 30 mg/day and tolvapt

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients after open heart surgery with cardiopulmonary bypass

Exclusion criteria

Exclusion criteria: Urgency or emergency operation CKD (dialysis, eGFR<30) Heart failure with EF<40% Heart failure or infection within preoperative 4 weeks Thoracoabdominal aortic replacement surgery and OPCAB Artificial respiration management over 24 hours and reintroduction Tolvaptan allergy Without feeling dry mouth or water ingestion Hypernatremia Patients with pregnant, possibility of pregnancy and pregnancy wish Using tolvaptan preoperatively

Design outcomes

Primary

Measure	Time frame
Whether returning to the target weight by the 6th postoperative day	—

Secondary

Measure	Time frame
worsening renal function, urine volume / body weight	—

Countries

Japan

Contacts

Public ContactTadaaki Koyama

Kobe City Medical Center General Hospital Cardiovascular Surgery

koyamat@kcho.jp078-302-4321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026